





Surveillance of healthcare-associated infections (HCAIs) South Africa Adriano G Duse, Chair: GARP-SA







Healthcare-associated infection (HCAI)-related AMR surveillance

- Currently, in most public SA healthcare facilities (HCFs) where HCAI AMR surveillance is carried out, it is mainly laboratory-based
 - Many downfalls to this approach
- In some public HCFs (particularly academic, tertiary) approach is enhanced by laboratory-based surveillance with ward liaison (LBSWL)

ince

Objectives of HCAI surveillance

- Reducing infection rates
- Establishing endemic baseline rates
- Identifying outbreaks
- Identifying risk factors
- Persuading medical personnel
- Evaluate control measures
- Satisfying regulators
- Document quality of care
- Compare hospitals' HCAI rates

DDEEP THE CENTER FOR Disease Dynamics, Economics & Policy WASHINGTON DC • NEW DELHI







S.A.Health-care-associated Infection Surveillance Centre.

Founder Members: Professor Emeritus Michael Emmerson, O.B.E.

- E.T.M. Smyth A.G. Duse J.R. Edwards T. Horan L. Doherty
- G. McIlvenny A. Nair M.E. Pringle G. Sharp

Room 3T05, Level 3, Wits Medical School Division of Clinical Microbiology and Infectious Diseases School of Pathology of the NHLS and University of the Witwatersrand, 7 York Road, Parktown, 2193 Johannesburg, South Africa











The Gauteng Pilot Study 2005 Background: A First Step In SA Surveillance Using Standardized Methodology & HCAI Definitions

- Study performed over a 3-month period, between March 2005 – May 2005
- Two academic, 2 provincial, 2 private hospitals
- Four HCAIs surveyed: ^{1ary} BSIs, UTIs, LRTIs (pneumonia), SSIs
- Total number of beds surveyed = 2 672





Aims of project:

- To pilot a automated data entry tool using manual questionnaires and an optical scanner tool that could be used for a Gauteng Provincial/National Nosocomial Infection Prevalence Survey – Pilot Study 2005
- To determine realistic, prevalence rates of uniformly defined HCAIs in South Africa's second most populated Province

And, ultimately (not done in this study, but being further developed):

Disease Dynamics, Economics & Policy

To profile the causative organisms of HCAIs with regard to their aetiology and antimicrobial resistance patterns

Antibiotic Resistance Partnership

Methodology:

Point-prevalence study

Disease Dynamics, Economics & P<u>olicy</u>

- NHSN definitions of HCAIs used
- Steps:
 - Design and generation of uniquely serialized paper survey forms for each healthcare facility (HCF)
 - Training in, and filling in of, survey forms
 - Return of completed survey forms to a centralized data processing facility
 - Automated data entry by scanning of forms using a high-speed optical scannea
 - Capturing and cleaning of data using Formic software
 - Exporting of data into SPSS & analysis, interpretation & recommendations
 - Confidential feedback to surveyed HCF for further action



Process:

- Training of surveyors January 25-27, 2005
- Validation: intra-, inter-, & external after 5d training
- "Start-up" talk at each participating facility; very NB for management "buy-in" – February 2005
- Delivery of questionnaires, commencement of survey & delivery of results – March – May 2005

CDDEP THE CENTER FOR Disease Dynamics, Economics & Policy WASHINGTON DC • NEW DELHI



Data collection form 1-General parameters:

- Patient demographics
- Medical risk factors
- Surgical risk factors & other invasive procedures
- Device-related risk factors
- Antibiotic and non-antibiotic therapy during admission





Surveillance of Healthcare-Associated Infection In Intensive Care

Surveillance Manual (Version 1.1) February, 2003

Developed by Infection Control Team The Royal Hospitals Belfast

1

QI	Survey date		Q2 Directorate	Q3 Ward number	Patient's name
ſ		Y Y Y Y			
Q4	Admission date to hose	bital	Q5 Hospital numbe	er en	Q6 Gender
	D D M M	Y Y Y Y			Male
Q7	Date of birth	Y Y Y Y	Q8 Admission type Elective Emerger Term lab	Q9 Was pa Yes, f Yes, f Our No	tient transferred? rom another hospital rom another ward
Q10	Admission diagnosis 1	choose from list Q11	Admission diagnosis 2	choose from list Q12 More	e than 2 diagnoses
ur i d	Major trauma COAD Stroke/paraplegi Diabetes Malnourished	a Smokin	ng C	Suprapubic Urethral closed None	duration (days)
Q16	Intravascular lines Venous (periph) Arterial (periph) Central PICC	Q17 >1 intravascular device Yes No	Q18 Duration of peripheral line	Q19 Duration of central line	Q20 Duration of other vascular device
Q21	Therapy this admission Steroids Blood Chemotherapy Cytotoxic	022 Antibiotics this admission No Prophylaxis	Ω23 Non-surgical br	eak in skin 024 Type	e of break Vascular ulcer Pressure sore Vascular & pressure Diabetic ulcer Other
Q25	Has patient undergone any form of surgery? YesNo	Q26 Surgical Q drains in-situ? Yes No	27 Has pt undergone any other invasive procedure? Yes No	Q28 Other invasive pr ERCP Percutaneous Other endosc but incl. gastr: Other invasive Other invasive	ocedures drainage procedure opy (excl. surgery stomy insertion) ve procedure



CDDEP

THE CENTER FOR Disease Dynamics, Economics & Policy WASHINGTON DC • NEW DELHI



HCAI–specific information

Isolate information including AMR





The Royal Hospitals	Hospital Infection Survey	01/RVH/01	
Bellast BT12 6BA	Surgical Site Infection		
Patient's name (not included in database)	Q1 Serial number from Survey 112	Q2 Type of SSI Superficial Deep	Q4 Type of specimen re Blood culture Incisional site of Trapped sputu Vascular cathe
Q3 Date of operation	Q4 Endoscopic approac	ch Q5 General anaesthetic this operation	Q5 Hospital code
	Yes N	lo Yes No	Q9 Sensitivities 1st iso
Q6 Date of surgical site infectio			Amikacin Amphotericin Amoxycillin Ampicillin Aztreonam
Q7 SSI operation class Clean Clean / contaminated Contaminated Dirty / Infected	Q8 Surgical site Head / Neck Chest Abdomen Urogenital tract Upper limb Lower limb		Cefixime Cefazime Ceftaidime Ceftriaxone Cefuroxime Chloramphenicol Ciprofloxacin Clindamycin Erythromycin 5-Filurdonaine
Q9 SSI culture result Positive Negative Unknown Not done	Q10 Antibiotic RX for infection Yes No		Fluconazole Fusidic acid Gentamicin Imipenem Meropenem Methicilin Metronidazole
Q11 SSI Community acquired Hospital acquired	Q12 Certainty of diagnosis Possible Probable Certain		Netilmicin Nitrofurantoin Ofloxacin Penicillin Piperacillin Rifampicin Taz/Pip Teicoplanin T
E	nter isolate information on Survey 20 fo		Tetracycline Tobramycin Trimethoprim Vancomycin Extra 1





CDDEP THE CENTER FOR Disease Dynamics, Economics & Policy

Why automated data entry (ADE) using manual questionnaires & optical scanning?

- System accessible to all HCFs once questionnaires completed, sent to centralized data processing unit -> cost effective; rapid feedback
- Patient-based, not isolate-based
- ICN at cold interface; not in office / laboratory
- Improved speed & accuracy of data entry; substantial cost savings [Infect Control Hosp Epidemiol. 1997 Jul; 18(7):486-491]
 - 22-fold productivity increase cf. manual data entry (MDE) with validation
 - Saving of \$ 0.63 [~ R 4.12] per questionnaire in clerical time
 - After validation, error rate of < 0.2 errors / 1000 responses (ADE) vs. 12.4 errors / 1000 responses (MDE)





Active Infections (# 2672 patients)

Surgical site infection

- 3.0%
- Bloodstream infection
- 5.01%
- Urinary tract infection
- 1.53%
- Respiratory tract infection
- 2.88%

CDDEP THE CENTER FOR Disease Dynamics, Economics & Policy WASHINGTON DC • NEW DELHI



Overall prevalence rate for the 4 surveyed infections: 9.73% (260/2672)

	BSI rate	UTI rate	RTI rate	SSI- all	SSI- surgical	Prevalence rate for 4 active infections surveyed
Hospital #1 (731 beds surveyed)	6.7	1.1	1.2	0.8	1.4	9.05
Hospital #2 (593 beds surveyed)	4.9	3.0	4.4	1.7	2.9	11.17
Hospital #3 (376 beds surveyed)	10.4	0.5	3.2	1.9	2.8	15.73
Hospital #4 (532 beds surveyed)	1.5	0.8	0.6	2.3	1.7	5.08
Hospital #5 (214 beds surveyed)	1.9	3.7	10.7	0.9	1.5	15.42
Hospital #6 (226 beds surveyed)	2.2	0.4	1.8	0.4	0.9	4.02
CDDEP Disease Econom	R FOR Dynamics, iics & Policy					Antibiotic

Partnership

WASHINGTON DC • NEW DELHI

Service groups and infection rates:

	BSI rate	UTI rate	RTI rate	SSI- all	SSI- surgical	Prevalence rate for 4 active infections surveyed
Medical	4.7	3.0	1.6	0.3	0.5	8.7
Surgical	4.1	0.9	2.2	2.7	3.5	8.4
Intensive Care	12.5	4.5	17.9	1.8	2.3	28.6
Gynaecology and Obstetrics	0.6	0.6	0.9	1.7	3.3	3.5
Paediatrics	10.2	1.1	4.9	0.2	0.3	16.5
Other services	2.2	0.4	1.8	0.4	0.9	4.02
CDDEP Disease Econom	R FOR Dynamics, lics & Policy			-		Global Antibiotic Resistanc

Global Antibiotic Resistance Partnership

Risk factors: 63.9% (1695/2652) of patients had 1/> listed risk factors

- Urinary catheter: 19.9% of patients
 - Median duration of catheter = 4 days
 - 4.2% of patients with urinary catheter developed a UTI
 - 0.8% of patients without urinary catheter developed a UTI
- Peripheral vascular catheter: 52.9% of patients
 - Median duration of PVC = 3 days
 - 6.4% of patients with PVC developed BSI
 - 3.4% without PVC developed BSI
- Central intravascular catheter: 7.85%
 - Median duration of CVC = 5 days
 - 15.9% of patients with CVC developed BSI
 - 4.1% without CVC developed BSI

CDDEP Disease Dynamics, Economics & Policy WASHINGTON DC • NEW DELHI



Risk factors: 63.9% (1695/2652) of patients had 1/> listed risk factors

- Mechanical ventilation: 4.2% of patients
 - 20.5% of patients on ventilators developed a LRTI
 - 2.0% without developed LRTI
- Others:
 - Immunodeficiency: 12.1% of patients
 - Parenteral nutrition: 2.8% of patients
 - Neutropaenia: 2.7% of patients
 - Non-surgical skin breaks: 13.3% of patients
 - Non-surgical invasive procedures: 14.7% of patients
- Antibiotics: 56.8% (1494/2630) of patients received antimicrobials during this admission
 - Indication: Specific 16.6%; Empirical: 67.8%; Surgical prophylaxis: 9.7%; Other: 5.9%

THE CENTER FOR Disease Dynamics, Economics & Policy WASHINGTON DC • NEW DELHI



Future Directions of The Michael Emmerson SA-HISC

 Adding to paper survey forms direct web entry of data onto surveillance questionnaires

• Changing focus, in targeted settings from prevalence to incidence surveillance









WASHINGTON DC • NEW DELHI



Advantages of Web Forms (1)

- Improved accuracy from validation
- Timeliness of Results
- Increase response rates
- Gives a good impression of the organisation
- Longer forms
- Edit and Modify

Advantages to both survey administrators and respondents





Advantages of Web Forms (2)

- Reduce time to fill out
- Accessibility
- Access Restriction
- Eliminate paper and printing costs
- Eliminate mailing
- Eliminate data entry from paper
- Eliminate disposal of paper

CDDEP Disease Dynamics, Economics & Policy WASHINGTON DC • NEW DELHI



Web Forms – Home Page



Web Form Security

- Access via secure website
- Each project can have different access restrictions
- Password protected

Disease Dynamics,

Economics & Policy

 Restrict project to specified groups

🥏 Feedb	ack Survey - '	Web Forms			×	
General	Security Adv	anced			_	
Security Allow everyone access to this project - No Restrictions Restrict access to this project Require users to enter a password before being allowed to access this project Password : 						
Only allow access to members of the selected web groups Web Groups :						
Rem				Add		
Note: Web users belonging to the listed groups will not be required to enter the project password.						
		<u>o</u> ĸ	Cancel			



Submitting Web Forms

- Save partially completed forms
- Reload previously submitted forms and make them editable
- Restrict number of forms submitted for a project
- Restrict the number of forms an indivdual can submit

🐨 Feedback Survey - Web Forms	×
General Security Advanced	
Partially Completed Forms	
Allow users to save partially completed forms.	
Note: These forms will not appear in the project database until submitted by the user.	
Allow users to reload previously submitted forms.	
Make previously submitted forms re-editable	
Completion Restrictions	-
Restrict the number of forms that can be submitted via Web Forms for this project	
Maximum : 150	
Current count : 0 Reset	
Restrict the number of forms an individual web user can submit.	
Maximum : 2 Reset	
<u> </u>	





Validating Fields

- Each question has a field associated with it
- If validation rule not met error message appears
- Form cannot be submitted until errors are corrected
- Validation examples
 - Mandatory field (cannot be bypassed)
 - Validate a field by comparing other fields
 - "No" to SSI cannot gave "Date of SSI"
 - "Date of SSI" cannot be before "Date of admission" and cannot be before "Date of surgery"
 - Validate a field, against pre-set criteria
 - "Male" cannot have "caesarean section"
 - "Date of surgery" cannot be after current date or before start date of project
 - Use entries in an external search list or internal code list to validate responses
 - Create 'fixed list of possible responses
 - List of surgical procedures; microorganisms; antimicrobials



THE CENTER FOR Disease Dynamics, Economics & Policy

Validation rules in action

Bei Vision Company and Company	ns - Google Se		
+Web Fo	Neurosurgery WEB 2010		
Project Navigation NEXT PAGE PREVIOUS PAGE CANCEL CLEAR	Surveillance of Surgical	Public Health Agency Site Infections following Neurosurgery	Page 1 of 4
● SAVE ● SUBMIT	Completion errors from built-in valid	dation rules.	
Completion Errors Page One (3) HC number Mandatory Field Error (HC_number) Gender Mandatory Field Error (Gender) addate	Date of birth *mandatory entry	ISSION - 14 / 05 / 11	
Mandatory Field Error (addate) Page Two (3)	Infants - gestational age at birth Gender *mandatory entry	☐ Male	
	Date of admission *mandatory entry		
	Reason for operation	Primary operation	
	ie center for isease Dynamics, conomics & Policy		Global Antibiotic Resistand

е

Partnership

WASHINGTON DC • NEW DELH

	In	terna	l codes -	Picklist
--	----	-------	-----------	-----------------

ormic Web Forms - [Ne	eurosurgery WEB 2010 - Page 3 of 4] - Windows Internet Exp	lorer	-@×
► P http://10.2	210.18.24/Webforms/WebForm.aspx?ID=A067DB6A548849888421FI	148E158DA61 🔄 🖄 🧐 🔀 Live Se	earch
Edit view Favorites	s loois Help	en Den Sten Alte Marco Marco Anto Auto	
avorites 🙀 🖉 HES.		Eur ဤ On For NT NT NT	ug • 12 I Web •
Tormic webforms -	- Google Se Formic web Forms - [Neu X		Internal code list of
Web For	MS NEW YORK		memai code fist of
	Neurosurgery WEB 2010		Neurosurgerv
ject Navigation			
EXT PAGE	Healthcare number -	- DOB 14 / 05 / 11 Page 3 of 4	OPCS codes
REVIOUS PAGE	AREA - maximum of 2 responses		
ANCEL			
	🗆 Cranial 📄 Spinal 📄 CSF	Peripheral nerve Other - Chest, Neck, Abdominal wall	
UBMIT	Cranial procedure details		
	Cranial site	Supratentoral	
mpletion Errors		Infratentorial	
age Two (3)		Transsphenoidal	
		IT ENT	
	Cranial implant	Cranionlasty - artifical	
	1.1 Jan Sabara Warren dargeri (2005) Orbitation		
	Cranial procedure OPCS code		
	Chinal	A01.1 Hemispherectomy for epilepsy	
	Spineloite	A01.2 Temporal lobectomy for epilepsy	
	Spinal site	A01.8 Lesionectomy for epilepsy	
		A02.1 Craniotomy for lesion of frontal lobe	
		A02.3 Craniotomy for lesion of parietal lobe	
		A02.4 Craniotomy for lesion of occipital lobe	
	Spinal approach	A02.5 Craniotomy for lesion of cerebellum	
	Spinal implant		
	Spingl procedure OPOS and		
	Spinal procedure OFOS code		
	CSF		
5			
tart 🏾 🏉 Formic Wel	b Forms - [🔯 Microsoft PowerPoint - [📆 Formic Web Fo	rms User 🔄 Document 1 - Microsoft 🖓 Fusion Pro - Design 🛛 Search Desktop	우 🛐 « 광병) 10:01 Global
	ease Dynamics,		Antibio
Ecol	nomics & Policy		Resista
			Partnershi

CD

Opportunities?

- Collaborative surveillance activities with GARP-participating partners
 - In Africa ?
 - Or even broader ?

Let's talk! <u>Adriano.Duse@wits.ac.za</u> and <u>agdduse@icon.co.za</u>

THANK YOU!



